WallStreetZenWallStreetZen

NASDAQ: CRVS
Corvus Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for CRVS

Based on 2 analysts offering 12 month price targets for Corvus Pharmaceuticals Inc.
Min Forecast
$3.50+96.63%
Avg Forecast
$5.25+194.94%
Max Forecast
$7.00+293.26%

Should I buy or sell CRVS stock?

Based on 2 analysts offering ratings for Corvus Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRVS stock forecasts and price targets.

CRVS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-27
lockedlocked$00.00+00.00%2024-03-20

1 of 1

Forecast return on equity

Is CRVS forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.27%

Forecast return on assets

Is CRVS forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CRVS revenue forecast

What is CRVS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$2.0M
Avg 2 year Forecast
$10.5M
Avg 3 year Forecast
$47.8M

CRVS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRVS$1.78$5.25+194.94%Buy
PMVP$1.70$6.00+252.94%Strong Buy
LVTX$3.33$6.00+80.18%Buy
TPST$3.91$25.00+539.39%Strong Buy
ALVR$0.76$1.17+54.57%Hold

Corvus Pharmaceuticals Stock Forecast FAQ

Is Corvus Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CRVS) stock is to Buy CRVS stock.

Out of 2 analysts, 0 (0%) are recommending CRVS as a Strong Buy, 1 (50%) are recommending CRVS as a Buy, 1 (50%) are recommending CRVS as a Hold, 0 (0%) are recommending CRVS as a Sell, and 0 (0%) are recommending CRVS as a Strong Sell.

If you're new to stock investing, here's how to buy Corvus Pharmaceuticals stock.

What is CRVS's revenue growth forecast for 2026-2028?

(NASDAQ: CRVS) Corvus Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Corvus Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CRVS's revenue for 2026 to be $98,077,164, with the lowest CRVS revenue forecast at $98,077,164, and the highest CRVS revenue forecast at $98,077,164. On average, 1 Wall Street analysts forecast CRVS's revenue for 2027 to be $516,866,654, with the lowest CRVS revenue forecast at $516,866,654, and the highest CRVS revenue forecast at $516,866,654.

In 2028, CRVS is forecast to generate $2,341,592,291 in revenue, with the lowest revenue forecast at $2,341,592,291 and the highest revenue forecast at $2,341,592,291.

What is CRVS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CRVS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CRVS's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CRVS price target, the average CRVS price target is $5.25, with the highest CRVS stock price forecast at $7.00 and the lowest CRVS stock price forecast at $3.50.

On average, Wall Street analysts predict that Corvus Pharmaceuticals's share price could reach $5.25 by Mar 27, 2025. The average Corvus Pharmaceuticals stock price prediction forecasts a potential upside of 194.94% from the current CRVS share price of $1.78.

What is CRVS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CRVS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.